• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Difference of natural history between sporadic, TSC-related, and LAM-related AML.

Research Project

Project/Area Number 18K07645
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 52040:Radiological sciences-related
Research InstitutionJuntendo University

Principal Investigator

Kuwatsuru Ryohei  順天堂大学, 医学部, 教授 (40225313)

Co-Investigator(Kenkyū-buntansha) 加藤 仁美  順天堂大学, 医学部, 助教 (10621732)
岡田 慎悟  順天堂大学, 医学部, 助教 (30773303)
Project Period (FY) 2018-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords腎血管筋脂肪腫 / 結節性硬化症 / リンパ脈管筋腫症 / 破裂 / 腎動脈塞栓術 / 散発性 / リンパ脈管筋腫症合併 / 結節性硬化症合併 / 腎機能 / 増大速度
Outline of Final Research Achievements

The total cases who received transcatheter arterial embolization (TAE) is 139 since July 2010 to March 2022. Both prophylactic TAE and TAE for ruptured angiomyolipoma (AML) were included. TAE was performed once in 62 cases and 2 times in 7 cases (10%) in sporadic AML patients. TAE was performed once in 24 cases and more than 2 times in 11 cases (31%) in Tuberous sclerosis(TSC) associated AML patients. TAE was performed once in 23 cases and more than 2 times in 12 cases (34%) in lymphangioleiomyomatosis (LAM) associated AML patients. As a result, TSC or LAM associated AML patients needs more than 3 times higher TAEs than sporadic AML.

Academic Significance and Societal Importance of the Research Achievements

本研究では、腎血管筋脂肪腫を、① 散発性腎血管筋脂肪腫、②リンパ脈管筋腫症合併腎血管筋脂肪腫、③ 結節性硬化症合併腎血管筋脂肪腫、④リンパ脈管筋腫症および結節性硬化症合併腎血管筋脂肪腫の4つのグループに分けて、腫瘍および腫瘍内動脈瘤が増大しまたは破裂し動脈塞栓術が必要になる頻度を検討した。症例数が少ないため、③と④を同一グループとして解析したが、今回のグループ分け後の分析により散発性腎血管筋脂肪腫で2回目の動脈塞栓術が必要となる頻度が10%と低く、他の2群では30%以上の症例で2回以上の動脈塞栓術が必要であることを明確にした。従ってこれらの群でより密な経過観察が必要であることが明らかになった。

Report

(5 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (3 results)

All 2019 2018

All Journal Article (3 results) (of which Peer Reviewed: 3 results,  Open Access: 2 results)

  • [Journal Article] Can we predict the existence of extrarenal feeders to renal angiomyolipomas?2019

    • Author(s)
      Zhang X, Kuwatsuru R, Toei H, Yashiro D, Okada S, Kato H
    • Journal Title

      Eur Radiol

      Volume: 29 Issue: 5 Pages: 2499-2506

    • DOI

      10.1007/s00330-018-5877-1

    • Related Report
      2019 Research-status Report 2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Superselective Transcatheter Arterial Embolization for Large Unruptured Renal Angiomyolipoma in Lymphangioleiomyomatosis2018

    • Author(s)
      Kato Hitomi、Kuwatsuru Ryohei、Inoue Tatsuro、Okada Shingo、Aida Mari、Yamashiro Yuki
    • Journal Title

      Journal of Vascular and Interventional Radiology

      Volume: 29 Issue: 7 Pages: 958-965

    • DOI

      10.1016/j.jvir.2017.11.003

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Postembolization Intratumoral Chronic Bleeding, without the Classic CT Feature of Active Extravasation, in Tuberous Sclerosis Complex-Related Renal Angiomyolipoma: Two Case Reports2018

    • Author(s)
      Zhang Xixi、Kuwatsuru Ryohei、Toei Hiroshi、Yashiro Daisuke、Okada Shingo、Kato Hitomi
    • Journal Title

      Case Reports in Nephrology and Dialysis

      Volume: 8 Issue: 2 Pages: 112-119

    • DOI

      10.1159/000489924

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access

URL: 

Published: 2018-04-23   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi